Search Videos and More

Showing 1 - 12 of 13 results

Previous| 1 | 2 |Next


2022 Society of Gynecologic Oncology (SGO) Symposium

2022 Society of Gynecologic Oncology (SGO)

DFCI Faculty share highlights from the Society of Gynecologic Oncology Annual Meeting on Women's Cancers held on March 18-21, 2022, in Phoenix, AZ and online.
Panos Konstantinopoulos, MD, PhD Shares Results of a Phase 2 Endometrial Cancer Study at 2022 SGO Video

Panos Konstantinopoulos, MD, PhD Shares Results of a Phase 2 Endometrial Cancer Study at 2022 SGO

Panos Konstantinopoulos, MD, PhD shares results of a phase 2, two-stage study of letrozole and abemaciclib in estrogen receptor (ER) positive recurrent or persistent endometrial cancer at the 2022 Society for Gynecologic Oncology Annual Meeting.
Ursula Matulonis, MD Shares Results of the SORAYA Study Video

Ursula Matulonis, MD Shares Results of the SORAYA Study

Ursula Matulonis, MD presented results of the SORAYA study at the 2022 Society for Gynecologic Oncology Annual Meeting.
Conjugate Therapy Produces Remissions in One-Third of Patients with Drug-Resistant Ovarian Cancer, Study Results Show News

Conjugate Therapy Produces Remissions in One-Third of Patients with Drug-Resistant Ovarian Cancer, Study Results Show

In a clinical trial involving patients with ovarian cancer previously treated with platinum-based chemotherapy, a novel “conjugate” therapy produced a substantially better response than standard treatments. Results from this study were presented by Dana-Farber's Ursula Matulonis, MD during a plenary session at the SGO 2022 Annual Meeting.
Drug Combination Shows Effectiveness in Patients with Recurrent ER-Positive Endometrial Cancer News

Drug Combination Shows Effectiveness in Patients with Recurrent ER-Positive Endometrial Cancer

A combination therapy that targets cancer cells from within and without caused tumors to shrink or stabilize in 75% of patients with recurrent or persistent estrogen receptor- (ER-) positive endometrial cancer. Results from this trial were shared by Panos Konstantinopolous, MD, PhD during a plenary session at the SGO 2022 Annual Meeting.
Implantable Device Helps Predict Drug Therapy Efficacy News

Implantable Device Helps Predict Drug Therapy Efficacy

Dana-Farber investigators recently launched a trial of a miniature device that can be implanted into ovarian tumors to deliver microdoses of different drugs, with the goal of rapidly measuring their effectiveness in killing cancer cells.
Genetic Signature of Tumor Cells Predicts Response to Chemotherapy Drug for Patients with Form of Ovarian Cancer News

Genetic Signature of Tumor Cells Predicts Response to Chemotherapy Drug for Patients with Form of Ovarian Cancer

For more than two decades, the chemotherapy drug gemcitabine has been a mainstay treatment for several types of cancer, producing remissions in many patients on its own or conjunction with other drugs. Now, scientists at Dana-Farber Cancer Institute have uncovered, for the first time, genetic evidence of which patients with high-grade serous ovarian cancer (HGSOC) are likely to benefit from the drug.
Newsweek Names Dana-Farber #3 in the World for Cancer News

Newsweek Names Dana-Farber #3 in the World for Cancer

Dana-Farber Cancer Institute has been named one of the world’s very best cancer hospitals by Newsweek in its new World’s Best Specialized Hospitals 2022 rankings.
Researchers Set Sights on New Ovarian Cancer Treatment Strategies News

Researchers Set Sights on New Ovarian Cancer Treatment Strategies

Despite breakthrough treatments for high-grade serous ovarian cancer, about 80 percent of patients relapse within two years, often resistant to treatment. The good news is that Dana-Farber scientists are pursuing multiple avenues of research that very well may improve outcomes.
Dana-Farber Scientists Work to Accelerate Development for Blood Tests for Ovarian Cancer News

Dana-Farber Scientists Work to Accelerate Development for Blood Tests for Ovarian Cancer

A new partnership between researchers at Dana-Farber Cancer Institute and University College London (UCL) may prove decisive in the quest to develop the first blood test for early-stage ovarian cancer.
Study Uncovers Potent Immunotherapy Approach to Ovarian Cancer Treatment News

Study Uncovers Potent Immunotherapy Approach to Ovarian Cancer Treatment

Immune therapies declare open season on cancer, rousing immune system cells to take up an attack on tumors. But which immune cells join the hunt, which sit it out, and what happens within immune cells that causes them to go on the offensive?
New Targeted Agent Achieves Impressive Response Rate in Trial with Patients with Uterine Serous Carcinoma News

New Targeted Agent Achieves Impressive Response Rate in Trial with Patients with Uterine Serous Carcinoma

In its first clinical trial in patients with a hard-to-treat form of uterine cancer, a targeted drug that subjects tumor cells to staggering levels of DNA damage caused tumors to shrink in nearly one-third of patients, investigators at Dana-Farber Cancer Institute reported.

Showing 1 - 12 of 13 results

Previous| 1 | 2 |Next